jump to content  sitemap
Division of Human Genetics : Department of Internal Medicine : College of Medicine : The Ohio State University
http://internalmedicine.osu.edu/cardiovascular//genetics/4754.cfm

 
Recent Publications
:: Directory ::
Faculty
Doreen Agnese, MD
Kirk Mykytyn, PhD
Amanda Toland, PhD
Judith Westman, MD
Genetic Counselors
Fellows
Research Coordinators
Staff

Home > Directory > Faculty > Amanda Toland, PhD > Recent Publications

Amanda Ewart Toland, PhD
(614) 247-8185
amanda.toland@osumc.edu


Recent Publications

Spearman AD, Sweet K, Zhao XP, McLennan J, Couch FJ, Toland AE. Clinically Applicable Models for the characterization of BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol, in press, 2008.

Toland AE, Rozek LS, Presswala, S, Rennert G, Gruber SB. PTPRJ haplotype confers increased risk in colorectal cancer. Cancer Epidemiol, Biomarkers Prev;17(10), in press, 2008

Fleming JL, Huang T H.-M., Toland, AE. The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res 68(22), in press, 2008.

Chen, Ying, Toland AE, McClennan J, Fridlyand J, Ziegler J, Crawford B, Costello J Ziegler J. Lack of Germline Promoter Methylation in BRCA1 Negative Families with Familial Breast Cancer. Genetic Testing 10:281-284, 2006.

Ewart-Toland, A, Yankowitz, J, Winder, A, Imagire, R, Cox, VA, Aylsworth, AS, and Golabi, M.  Oculoauriculovertebral abnormalities in children of diabetic mothers. Am J Med Genet 90: 303-309 2000.

Qiu, J, Ogus, S, Mounzih, K, Ewart-Toland, A and Chehab, FF. Leptin-deficient mice backcrossed to the BALB/cJ genetic background have reduced adiposity, enhanced fertility, normal body temperature, and severe diabetes. Endocrinology 142:3421-3425, 2001.

Chehab, FF, Qiu, J, Mounzih, K, Ewart-Toland, A, and Ogus, S. Leptin and reproduction. Nutr Rev 60:S39-46, 2002.

Ewart-Toland, A, Briassouli, P, de Koning, JP, Mao, J-H, Yuan, J, Chan, F., MacCarthy-Morrogh, L, Ponder, BAJ, Nagase, H, Burns, J, Ball, S, Almeida, M, Linardopoulos, S, and Balmain A. Identification of Stk6/STK15 as a candidate modifier of cancer risk in mouse and man. Nat Genet 34: 403-412, 2003.

Ewart-Toland, A, Chan, J, Yuan, J, Balmain, A. and Ma, J. TGFB-1 polymorphisms may be associated with late stage prostate cancer.  Cancer Epidemiol Biomarkers Prev 13: 759-764, 2004.

Dai,Q,  Cai, Q-Y, Shu, X-O, Ewart-Toland, A, Wen, W-Q, Balmain, A, Gao, Y-T, and Zheng, W. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13: 2065-2070, 2004.

Ewart-Toland, A, Dai, Q, Gao, Y-T, Nagase, H, Dunlop, MG, Farrington, SM, Barnetson, RA, Anton-Culver, H, Peel, D, Ziogas, A, Lin, D, Miao, X, Sun, T, Ostrander, EA, Stanford, JL, Langlois, M, Chan, JM, Yuan, J, Harris, CC, Bowman, ED, Clayman, GL, Lippman, SM, Lee, JJ, and Balmain, A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis, 26: 1368-1373, 2005.

Symposium articles:
Ewart-Toland, A and Balmain, A.  The Genetics of Cancer Susceptibility: From Mouse to Man Tox Pathol 32(Suppl 1): 26-30, 2004.

Book Chapters:

Ewart Toland A. Mouse Models. In Encyclopedia of Cancer 2nd Edition. Ed. M. Schwab. Springer-Verlag, Heidelburg, 2008. 

 

Dworkin AM, Huang T, Ewart Toland A. The role of epigenetics in breast cancer: Implications for diagnosis, prognosis and treatments.  In Pharmacogenetics of Breast Cancer: Towards the Individualization of Therapy. Ed. B.L. Jones. Informa Health Care Publisher, New York, 2008.

Chehab, FF, Ewart-Toland, A, Mounzih, K, Qiu, J and Ogus, S. Genetics and physiology link leptin to the reproductive system. In Leptin and Reproduction. Eds. M.C. Henson and V.D. Castracane.  Kluwer Academic/Plenum Publishers. New York, 2003.


Department of Internal Medicine http://www.internalmedicine.osu.edu

The Ohio State University | College of Medicine
Department of Internal Medicine | Division of Human Genetics
2001 Polaris Parkway | Columbus, OH 43240
Ph: 614.293.6694 | Toll-Free: 888.329.1654 | Contact Us